Episode 52
Biotech Hangout
00:00
Eli Lilly's Proactive Pricing Plan for Insulin
Eli Lilly is cutting the cost of the best-selling insulin by 70% and they're going to cap. Patient out of pocket costs for all insulin's at 35 dollars or less per month. By doing this they're actually going to avoid paying big Medicaid rebates so if Lilly's price hikes for insulin rose faster than inflation and the company would have been penalized by Medicaid however since it's lowering prices of cumulative by 70% it won't face that penalty.
Transcript
Play full episode
